Chinese Scientists Use TriAltus Bioscience’s CL-7 Purification System to Purify CRISPR-associated Proteins

BIRMINGHAM, Ala. (August 29, 2018)—TriAltus Bioscience, LLC today announced that scientists at Hubei University in China successfully co-expressed and purified ribonucleoprotein complexes—including Cas9 and Cas12a CRISPR-associated proteins—from E. coli in a single step using the company’s licensed CL-7 purification technology. The Hubei scientists published the results of their work in late July.

“This team’s success with CRISPR proteins independently validates our CL-7 purification system as a way to efficiently purify some of the most important proteins being used in therapeutic research,” said Bob Shufflebarger, CEO and co-founder of TriAltus Bioscience. “We believe this technology will enhance scientific research, resolve some of the challenges of working with genetically-engineered proteins, and ultimately help reduce industry costs associated with biopharmaceutical production.”

In their paper, the Hubei scientists wrote: “By harnessing the ultra-high-affinity CL7/Im7 purification system, we achieved one-step purification of pure Cas RNP with profound nuclease activity in vitro and in vivo, indicating that the method has great potential to prepare CRISPR-associated nucleases at large-scale, low cost and short time.”

The paper also stated that “[This] method is convenient, cost-effective, and applicable to prepare other CRISPR associated nucleases.”

CRISPR—an acronym for Clustered Regularly Interspaced Short Palindromic Repeats—is a gene editing tool that effectively and specifically changes genes within organisms. CRISPR-associated (Cas) proteins such as Cas9 and Cas12a are requisite components of the CRISPR system, which researchers are increasingly using to find potential treatments for diseases like cancer, HIV, and sickle cell disease.

TriAltus Bioscience co-founder, Dmitry Vassylyev, Ph.D., professor of Biochemistry and Molecular Biology at UAB, led the team that invented the CL-7 technology. Vassylyev tested the method on five notoriously challenging biological molecules with remarkable results. The work was published in 2017 in the Proceedings of the National Academy of Sciences (PNAS).


Trialtus Bioscience, LLC ( provides life scientists with tools for production and purification of genetically engineered proteins. Our novel affinity tag system delivers proteins with ultra-high purity and yield in a single step. The CL-7 affinity tag protein purification system was licensed by TriAltus Bioscience from the University of Alabama at Birmingham (UAB) and is now commercially available. For more information, contact or call 1-800-417-7688.


Nancy Wenger, Director of Business Development,